Literature DB >> 3819423

Impending pathologic fractures from metastatic malignancy: evaluation and management.

K D Harrington.   

Abstract

Both lytic and blastic long bone metastases are at risk to develop pathologic fractures in instances where more than 50% of the circumferential cortical bone has been destroyed or where the pain with weight-bearing stresses persists, increases, or recurs despite adequate local irradiation. Moreover, those most commonly encountered lesions of the proximal femur are at high risk to fracture if they are in excess of 2.5 cm in any dimension or if they are associated with avulsion of the lesser trochanter. Such lesions should be treated aggressively by prophylactic internal fixation. This will avoid the development of a secondary fracture with its concomitantly high risk that true bony healing will not occur even with adequate fixation. When internal fixation is chosen for a large metastasis with extensive cortical destruction, that fixation should be augmented by debulking of the lesion and by packing it with methylmethacrylate polymerizing in situ. Such an expedient not only improves the efficacy of subsequent radiotherapy but also prevents shortening of the bone with weight bearing while enhancing the torque capacity and sheer resistance inherent in the metal fixation device.

Entities:  

Mesh:

Year:  1986        PMID: 3819423

Source DB:  PubMed          Journal:  Instr Course Lect        ISSN: 0065-6895


  26 in total

1.  Subtrochanteric metastatic lesions treated with the long gamma nail.

Authors:  S R Samsani; V Panikkar; D Georgiannos; D Calthorpe
Journal:  Int Orthop       Date:  2003-06-11       Impact factor: 3.075

2.  Prophylactic Percutaneous Consolidation of Large Osteolytic Tumors of the Pelvic Ring Using Fixation by Internal Cemented Screws.

Authors:  Jessica Assouline; Lambros Tselikas; Charles Roux; Steven Yevich; Alexandre Delpla; Arash Najafi; Marc Al Ahmar; Jean-Charles Bijot; Thierry de Baère; Frédéric Deschamps
Journal:  Radiol Imaging Cancer       Date:  2021-05

Review 3.  Percutaneous Fixation by Internal Cemented Screw for the Treatment of Unstable Osseous Disease in Cancer Patients.

Authors:  Frederic Deschamps; Steven Yevich; Guillaume Gravel; Charles Roux; Antoine Hakime; Thierry de Baère; Lambros Tselikas
Journal:  Semin Intervent Radiol       Date:  2018-11-05       Impact factor: 1.513

4.  In brief: classifications in brief: Mirels' classification: metastatic disease in long bones and impending pathologic fracture.

Authors:  Muhammad Umar Jawad; Sean P Scully
Journal:  Clin Orthop Relat Res       Date:  2010-10       Impact factor: 4.176

5.  Incidence and outcome of bone metastatic disease at University Malaya Medical Centre.

Authors:  Vivek Ajit Singh; Amber Haseeb; Alla Allden H Ali Alkubaisi
Journal:  Singapore Med J       Date:  2014-10       Impact factor: 1.858

6.  What Is the Adverse Event Profile After Prophylactic Treatment of Femoral Shaft or Distal Femur Metastases?

Authors:  Ryan P McLynn; Nathaniel T Ondeck; Jonathan N Grauer; Dieter M Lindskog
Journal:  Clin Orthop Relat Res       Date:  2018-12       Impact factor: 4.176

Review 7.  A Focused Review of Safety Considerations in Cancer Rehabilitation.

Authors:  Susan Maltser; Adrian Cristian; Julie K Silver; G Stephen Morris; Nicole L Stout
Journal:  PM R       Date:  2017-09       Impact factor: 2.298

8.  Mirels' rating for humerus lesions is both reproducible and valid.

Authors:  Andrew R Evans; John Bottros; William Grant; Benjamin Y Chen; Timothy A Damron
Journal:  Clin Orthop Relat Res       Date:  2008-03-21       Impact factor: 4.176

9.  Can certain benign lesions of the proximal femur be treated without surgery?

Authors:  Seung Han Shin; Ingwon Yeo; Sung Wook Seo
Journal:  Clin Orthop Relat Res       Date:  2013-05-14       Impact factor: 4.176

Review 10.  Role of stereotactic body radiotherapy in spinal metastasis and subsequent fracture risk: identifying and treating the at-risk patient.

Authors:  Mekhail Anwar; Igor J Barani
Journal:  CNS Oncol       Date:  2013-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.